# A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes

> **NCT04017832** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 1441 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Oral semaglutide
- **DRUG:** Sitagliptin
- **DRUG:** Placebo (oral semaglutide)
- **DRUG:** Placebo (sitagliptin)

## Key facts

- **NCT ID:** NCT04017832
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-29
- **Primary completion:** 2021-10-27
- **Final completion:** 2021-10-27
- **Target enrollment:** 1441 (ACTUAL)
- **Last updated:** 2024-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04017832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04017832, "A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04017832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*